XKR9 was found to be down‐regulated in AS cancer patients in both the AS vs. CA comparison (log2 fold change = −1.58; adjusted p‐value = 1.50e‐39) and the AS vs. AA comparison (log2 fold change = −1.08; adjusted p‐value = 6.01e‐08). This evidence concerns the gene XKR9 and cancer.